Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01114711
Other study ID # 2009-P-001452
Secondary ID 400479
Status Terminated
Phase
First received April 29, 2010
Last updated April 10, 2018
Start date April 2010
Est. completion date May 2010

Study information

Verified date April 2018
Source Mclean Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

We are looking for women who suffer from menstrual migraine to participate in a 2-visit migraine brain imaging research study. Our goal is to see how the menstrual migraine brain's pain pathways function when the migraineur has been taking Frovatriptan. During the screening visit (Visit 1) participants will sign the informed consent form, complete questionnaires, meet with the study physician, and have QST (quantitative sensory testing: to determine your pain thresholds for a heat stimulus) performed. For Visit 2's MRI scan, subjects will be asked to lie very still while the scan is occurring. In some parts, they will not have to do anything, while in others they will be asked to rate pain and unpleasantness for brush and thermal stimuli. Participants are compensated for both visits.


Recruitment information / eligibility

Status Terminated
Enrollment 24
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Female

- Regular Menstrual Phase

- Menstrual Migraine

- No significant medical history (Significant medical history of such as seizure disorder, diabetes, alcoholism, cardiac disease including coronary artery disease, psychiatric problems; drug addiction, respiratory problems, liver disease, etc.)

- No significant medication history, except for migraine

- All patients will be currently taking or have previously taken triptan medications for migraine

- Weight, <285 pounds

- Not claustrophobic

- No contraindication to taking triptans

Exclusion Criteria:

- Age <18

- Significant medical problems (aside from pain before, during and after migraine episodes)

- Positive drug of abuse screen (excluding medications currently prescribed for their clinical condition, e.g. opioids, benzodiazepines, etc.)

- Positive alcohol screen

- Women taking oral contraceptives

- Claustrophobia

- History of dermatological hypersensitivity in the facial area

- Positive history of cardiac problems/ abnormalities seen in EKG at initial screening visit

- Pregnancy

- Sensory loss detected on Quantitative Sensory Testing at screening

- Significant alcohol history (ingestion of 5 or more glasses (> 40 oz) of alcohol per week)

- Metal implants of any type (including dental bridges, crowns, retainers, orthodontic devices e.g. braces, etc.)

- Tattoos containing metallic ink on the neck, shoulders, upper arm and head (which could become heated up in the scanner, and potentially cause blistering or burning)

- Cardiac pacemakers

- Aneurysm clips and other vascular stents, filters, clips or other devices

- Prosthetic heart valves

- Other prostheses

- Neuro-stimulator devices

- Implanted infusion pumps

- Cochlear (ear) implants

- Ocular (eye) implants or known metal fragments in eyes

- Exposure to shrapnel or metal filings (sheet metal workers, welders, and others)

- Other metallic surgical hardware in vital areas

- Use of any of the following medications:

- Propanolol/ Inderol

- SSRI's: citalopram/ Celexa, Lepraxo, paroxetine/ Paxil, fluoxetine/ Prozac, Sarafem, Symbyax, sertraline/ Zoloft, Fluvoxamine/ Luvox

- SNRI's: duloxetine/ Cymbalta, venlafaxine/ Effexor

- triptans: sumatriptan/ Imitrex, naratriptan/ Amerge, zolmitriptan/ Zomig, rizatriptan/ Maxalt, eletriptan/ Relpax, almotriptan/ Axert

- ergotamine type medicines: Bellergal, Cafergot, Ergomar, Wiraine, Migranal/ DHE45, Sansert

- ketoconazole (Nizoral, Fungoral)

- itraconazole (Sporanox)

- ritonavir (Norvir)

- erythromycin (Erythrocin)

Study Design


Locations

Country Name City State
United States Neuroimaging Center, McLean Hospital Belmont Massachusetts

Sponsors (2)

Lead Sponsor Collaborator
Mclean Hospital Endo Pharmaceuticals

Country where clinical trial is conducted

United States, 

See also
  Status Clinical Trial Phase
Completed NCT04600388 - Efficacy and Safety of Nerivio for the Acute Treatment of Menstrual Migraine
Not yet recruiting NCT03702114 - Detecting Auricular Points in MMG by a Novel APD ( APD-MMG )
Not yet recruiting NCT02592681 - Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine N/A
Completed NCT01329562 - CGRP, Estrogen, Cortisol, VIP, α-Amylase, PGE2, PGI2 and ß-Endorphin Levels in Menstrual Migraine Before and After Treximet Phase 4
Recruiting NCT06173661 - Fremanezumab Treatment of Migraine in Women With Menstrual Migraine Ages 18-45 Phase 4
Recruiting NCT03152305 - Intracranial Pressure During Migraine N/A
Completed NCT01578941 - An Investigation of the Safety and Utility of Treximet in the Treatment of Menstrual Migraine Phase 4
Completed NCT04102995 - A Study Investigating the Efficacy and Safety of Sepranolone in Women With Menstrual Migraine Phase 2
Terminated NCT01395264 - Saccadometry in Primary Headache Syndromes N/A